We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LZB:NYSELa-Z-Boy Incorporated Analysis

Data as of 2026-06-17 - not real-time

$35.06

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

La‑Z‑Boy just reported a strong fiscal Q4, highlighted by retail sales growth. Margins improved, with operating margin climbing to 5.4% and profit margin to 3.9%. The company completed the sale of its American Drew and Kincaid wholesale case‑goods businesses, sharpening focus on higher‑margin upholstered lines. Revenue rose 3.8% year‑over‑year to $2.13 B. Forward EPS guidance of $3.29 translates to a forward PE near 10.7. Analysts have issued a “buy” rating with a median price target of $44.5. The stock opened at $37.99 and is now trading at $35.06, below the 20‑day SMA of $36.89 and the 50‑day SMA of $35.64. RSI sits at 42, indicating neutral momentum, while volume is trending upward. Market sentiment is in Extreme Greed (FGI 92), adding a behavioral boost.
Valuation models place fair value at $67.08, implying roughly 27% upside. The current 2.56% dividend yield with a 45% payout is backed by solid operating cash flow and $194 M free cash flow. A beta of 0.89 and 30‑day volatility of 38% suggest moderate price swings. Consumer‑cyclical exposure brings higher sector risk, but low price‑to‑book (1.38) and price‑to‑sales (0.68) signal an undervalued profile. The blend of value metrics and modest growth steers the thesis toward a value play. Investors should watch the upcoming earnings call for confirmation of margin trends and guidance. Overall, the stock offers a compelling risk‑adjusted upside for patient investors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Upcoming earnings volatility
  • Bearish MACD histogram
  • Price near support levels

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Undervalued DCF with ~27% upside
  • Improving margins and dividend yield
  • Analyst buy rating and target price

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Sustainable dividend and cash flow
  • Strategic focus on higher‑margin segments
  • Long‑term value metrics (low P/B, low P/S)

Key Metrics & Analysis

Financial Health

Revenue Growth3.80%
Profit Margin3.93%
P/E Ratio19.0
ROE8.09%
ROA4.31%
Debt/Equity53.88
P/B Ratio1.4
Op. Cash Flow$237.7M
Free Cash Flow$194.7M

Technical Analysis

TrendBullish
RSI42.2
Support$33.49
Resistance$39.30
MA 20$36.89
MA 50$35.64
MA 200$35.44
MACDBearish
VolumeIncreasing
Fear & Greed Index92.13

Valuation

Fair Value$67.08
Target Price$44.50
Upside/Downside26.93%
GradeUndervalued
TypeValue
Dividend Yield2.56%

Risk Assessment

Beta0.89
Volatility37.82%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.